Introduction {#s1}
============

Preterm birth (PTB), the outcome of preterm labour (PTL), is a major cause of maternal and perinatal morbidity and mortality, occurring in ∼11% of recorded live births worldwide ranging from 5% in developed countries to 18% in developing countries ([@DMU008C25]). The exact cause of PTL is unknown, although the concomitant activation of endocrine and immune pathways are believe to drive events, resulting in spontaneous initiation of uterine contractions and cervical ripening (CR) ([@DMU008C172]; [@DMU008C203]; [@DMU008C237]). There is no fully effective agent for prevention of PTL. Progesterone (P4) to maintain uterine quiescence, and cervical cerclage to prevent premature CR have some efficacy in terms of reducing PTB, but there is little evidence of long-term beneficial effects for the baby ([@DMU008C8]; [@DMU008C131]). Similarly, short term, but not long-term, benefits were demonstrated in a recent network analysis of tocolytics ([@DMU008C94]). Thus, new strategies are needed.

Sex hormone steroids, including androgens, increase with normal pregnancy. The role of androgens in female physiology has been an active area of investigation for several decades. The major androgens synthesized in women are dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulphate (DHEAS), androstenedione (A4), testosterone (T) and dihydrotestosterone (DHT) ([@DMU008C32]; [@DMU008C125]; [@DMU008C206]) (Fig. [1](#DMU008F1){ref-type="fig"}). Although their impact on women\'s health has been investigated, particularly in the context of polycystic ovarian disease, the role they play during pregnancy remains less well described. A number of studies have explored androgenic actions in systems critical for pregnancy reaching term, and further understanding of their roles will facilitate management of potentially life-threatening complications for the mother and the fetus. Figure 1Testosterone metabolism. DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate, A4, androstenedione; T, testosterone; E1, estrone; E2, estradiol; E3, estriol; 3α-HSD, 3-α-hydroxysteroid dehydrogenase/Δ-5-4 isomerase; 3β-HSD, 3-β-hydroxysteroid dehydrogenase/Δ-5-4 isomerase; 17β-HSD, 17β-hydroxysteroid dehydrogenase; 3α-Adiol, 5α-androstane-3α, 17β-diol; 3β-Adiol, 5α- androstane-3β,17β-diol; DHT, dihydrotestosterone; STS, sulphatase; ST, sulfotransferase; 16α-OH, 16α-hydroxy.

Such key systems are cervical remodelling and myometrial contractility. In this review we discuss (i) the biosynthesis, clearance and availability of androgens during pregnancy, (ii) the associations of androgens with adverse pregnancy outcomes, (iii) the role of androgens in physiology of cervical remodelling and (iv) the roles of androgens in the physiology of the myometrial function with a focus on the crosstalk between androgens and myometrial contractile machinery.

Methods {#s2}
=======

Search strategy {#s2a}
---------------

We searched Pubmed using the keywords 'androgens' and 'pregnancy' to conduct to our knowledge the first narrative review decribing what is known about androgens during pregnancy. The initial Pubmed search identified 5976 manuscripts. Although the focus of this report was manuscripts published between 1980 and 2013, seminal references from 1930 to 1980 were included. For a study to be included in this review, it had to focus on potential roles for androgens in adverse pregnancy outcomes and processes involved in parturition, such as cervical remodelling and myometrial contractility. In addition, studies on androgen metabolism and papers documenting levels of androgens during pregnancy were included. Reports on the role of androgens on fetal gonadal development, fetal lung development and fetal immune system were not included. Following these inclusion and exclusion criteria, ∼500 studies were judged as relevant and used to form the basis of this review.

Results {#s3}
=======

Androgen biology during pregnancy {#s3a}
---------------------------------

Herein we introduce androgens in female physiology focusing on androgen biosynthesis and androgen metabolic clearance at the time of pregnancy. Concentrations of androgens in the feto-maternal unit throughout gestation are reviewed. Afterwards, we highlight studies correlating androgen levels in the feto-maternal unit with adverse pregnancy outcomes.

### Androgens in female physiology {#s3a1}

Androgens are critically important for the development of the male reproductive tract during fetal life and the maintenance of male secondary sexual characteristics in adulthood ([@DMU008C214]; [@DMU008C267]; [@DMU008C143]). Androgens can also act as pro-hormones for biosynthesis of estrogens in both sexes ([@DMU008C198]; [@DMU008C252]; [@DMU008C192]). In women, androgens are synthesized by cells within the ovaries, the adrenal glands, and also in fat, acting in an endocrine, paracrine or intracrine manner. In addition to playing key roles in the regulation of reproductive tissues such as the ovary and endometrium, androgens have a functional impact on the liver, kidney, bone and muscle ([@DMU008C31]; [@DMU008C265]; [@DMU008C216]). An excess production of androgens in women, for example in association with conditions such as polycystic ovarian syndrome (PCOS), can result in acne, hirsutism and infertility as well as to an increase in the risk of other complications, such as high blood pressure, cardiovascular disease and type 2 diabetes mellitus ([@DMU008C205]; [@DMU008C57]; [@DMU008C72]). Since the 1960s, it has been generally hypothesized that, during pregnancy, androgens act as substrates for estrogen formation in the placenta ([@DMU008C188]; [@DMU008C224]; [@DMU008C63]; [@DMU008C235]). According to this hypothesis, DHEAS, produced by the fetal adrenals, and to a smaller extent from the maternal adrenals, enters the placenta, where it is metabolized to A4 and T, which is then converted into E1 (estrone) ([@DMU008C242]). E1 is in turn converted into E2 (estradiol), which enters the fetal circulation where it is taken up by the liver and converted into E3 (estriol) ([@DMU008C101]; [@DMU008C213]). E3 can then pass to maternal circulation and be cleared in maternal urine ([@DMU008C269]). Androgen biosynthesis during pregnancy is extensively discussed later in this review and shown in Fig. [1](#DMU008F1){ref-type="fig"}.

### Androgen-dependent signalling {#s3a2}

The importance of the androgen receptor (AR) in mediating the effects of androgens is well documented. For example, mutations or deletions in the *AR* gene located on the X chromosome are associated in both man and mouse with failure to masculinize. This results in 'testicular feminization', a condition where a male with a 46XY karyotype is phenotypically female ([@DMU008C139]; [@DMU008C41]; [@DMU008C105]). The AR is a member of a superfamily of ligand-activated transcription factors; only T and DHT bind AR with high specificity and affinity ([@DMU008C180]). Ligand binding within the cytoplasm, where the classic AR resides, results in a conformational change in receptor protein, dimerization, nuclear translocation, association with co-factors and ultimately interaction with specific regions of the genome known as androgen response elements ([@DMU008C55]). The net result of these changes is an up- or down-regulation in gene expression. Such a response is termed 'genomic' as it involves gene transcription. In addition to their genomic effects, androgens are also able to exert their effects in a 'non-genomic' manner, independent of gene transcription or protein synthesis ([@DMU008C127]). Non-genomic effects of androgens involve interaction with the cell membrane via a number of signalling molecules, including membrane receptors, ion channels or enzyme-linked receptors and cytoplasmic regulatory proteins ([@DMU008C78]). These non-genomic effects are rapid and can be observed within seconds, in contrast to genomic effects, which may take hours or even days.

### Androgen biosynthesis {#s3a3}

The biosynthetic conversion of cholesterol (Ch) to androgens involves several steps and enzymes. A fundamental step in this process is the synthesis of pregnenolone. Only certain cell types in humans are capable of pregnenolone manufacture, including testicular Leydig cells, ovarian theca and corpus luteum cells, placental trophoblast cells, adrenal cortex cells and some specific cells in the brain (reviewed in [@DMU008C87]). Pregnenolone is metabolized to DHEA, which is further metabolized to A4, the precursor of T. T can be reduced to a number of androgens, such as 5α-DHT (DHT), 5β-DHT, 5β-androstandiol, 3α-Adiol, 3β-Adiol or further metabolized to estrogens. The reduction of T to DHT and the conversion of T to estrogens is catalysed by the metabolising enzymes 5α-reductase and aromatase (CYP19), respectively (Fig. [1](#DMU008F1){ref-type="fig"}). Androgen biosynthesis has been extensively reviewed by [@DMU008C179]).

In the non-pregnant premenopausal woman, ∼50% of all DHEA is secreted by the adrenal glands, 20% from the ovaries and 30% from the peripheral tissues ([@DMU008C3]). In contrast, the adrenals and ovaries produce equal amounts of A4 ([@DMU008C135]). Regarding T, ∼50% is equally synthesized in the ovaries and adrenals and the other half is produced from A4 in the peripheral tissues ([@DMU008C187]). Finally, DHT is not secreted by the endocrine glands, and this androgen is synthesized from T in the peripheral androgen target tissues ([@DMU008C109]; [@DMU008C149]). During pregnancy, an additional source of androgens is the fetus and the placenta. In particular, the developing fetus is the source of placental 16α-hydroxy-DHEA, a product of 16α-hydroxylation of DHEAS in the fetal liver ([@DMU008C35]). In a similar way to its non-16α-hydroxylated form, 16α-hydroxy-DHEA can be metabolized to 16α-hydroxy-A4. The latter is the predominant source of E3 ([@DMU008C157]) (Fig. [1](#DMU008F1){ref-type="fig"}).

Once synthesized, androgens enter the maternal circulation, where their levels can be detected. Usually T levels are reported as either total (tT) or 'free' (fT) with an important distinction between them; the latter are unbound to plasma proteins, such as sex-hormone-binding globulin (SHBG), and therefore able to pass freely across plasma membranes to interact with AR, whereas bound T is unable to penetrate the cell membrane ([@DMU008C155]). The percentage binding of SHBG is greater for DHT (59%) than for T (44%) and E2 (20%) and is very low for A4, DHEA, E1 and E3 ([@DMU008C15]). The affinity of each androgen for SHBG is dependent on their structural characteristics. For example, a 17β-OH group and a 5α-hydrogen moeity increase the affinity for SHBG binding, whereas androgens with either a double bond in ring A or an aromatic ring A are less SHBG potent ([@DMU008C225]). Therefore, DHT, which has both the 17β-OH group and a 5α-hydrogen atom, has 2-fold greater affinity for SHBG than T, which has a double bond in ring A ([@DMU008C225]).

### Concentrations of androgens during pregnancy {#s3a4}

A number of studies have reported elevated levels of some, but not all, circulating androgens during normal pregnancy ([@DMU008C159]; [@DMU008C197]; [@DMU008C207]; [@DMU008C53]; [@DMU008C33]; [@DMU008C17]).

A notable increase in tT is observed from the first trimester of pregnancy and further elevations are reported towards term ([@DMU008C207]; [@DMU008C17]; [@DMU008C22]). However, circulating fT levels only increase significantly at the third trimester of pregnancy ([@DMU008C53]). In addition, serum A4 is significantly elevated between 37--42 weeks of pregnancy compared with non-pregnant levels, but the relative increase of T during pregnancy is greater than the increase in A4 ([@DMU008C159]). In contrast, maternal circulating DHEAS levels fall across gestation to ∼50% of the non-pregnant levels ([@DMU008C156]). Finally, SHBG levels increase during the first trimester of pregnancy and continue to increase dramatically throughout mid and late gestation ([@DMU008C268]). Table [I](#DMU008TB1){ref-type="table"} summarizes the maternal serum levels of different androgens during pregnancy and Fig. [2](#DMU008F2){ref-type="fig"} is a graphical representation of this information. Table ILevels of androgens in maternal serum.AndrogenNon-pregnantFirst trimesterSecond trimesterThird trimesterReferencesfT (pmol/l)6.211.17.513.3[@DMU008C268]tT (mmol/l)0.21--2.980.90--7.321.20--8.402.20--10.70[@DMU008C176]A4 (ng/ml)1.0--2.02.5--3.50.6--7.81.6--14.0[@DMU008C40], [@DMU008C37]DHT (ng/ml)0.022--0.1070.1130.180.1--0.3[@DMU008C33], [@DMU008C53]SHBG (nmol/l)42.268.1279.3246.1[@DMU008C268]DHEA (nmol/l)1.0--40.010.0--60.05.0--50.05.0--50.1[@DMU008C243]DHEAS (nmol/l)2000--40002000--4000500--2000500--200[@DMU008C243][^1] Figure 2Graphical presentation of the highest (**A**) and lowest (**B**) levels of androgens in maternal serum throughout gestation. tT, total testosterone; fT, free testosterone; SHBG, sex hormone-binding globulin; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate; A4, androstenedione; DHT, dihydrotestosterone.

In the fetus, levels of some androgens are dependent on fetal sex and gestation. In fetal blood, T levels are higher in males ([@DMU008C201]). This contrasts with DHT levels, which are similar in both sexes ([@DMU008C60]; [@DMU008C201]). In male fetuses, serum concentrations of T increase until the end of first trimester, reaching a peak of 150 ng/ dL at the end of week 12 of gestation, after which they decline by 70% to a nadir at 23 weeks ([@DMU008C201]). In female fetuses, T levels remain generally lower throughout first and second trimester (50 ng/dL) and decline rapidly at term ([@DMU008C60]). In addition to T, DHEA levels are higher in cord blood of male fetuses compared with females, whereas A4 levels are similar ([@DMU008C118]). Labour is associated with increased levels of cord blood A4, DHEA and SHGB and decreased levels of tT and fT ([@DMU008C118]). In amniotic fluid, T and A4 are higher in male-bearing pregnancies ([@DMU008C38]). On the other hand, there is no notable difference in amniotic fluid DHEA levels between male and female fetuses ([@DMU008C199]). Although T levels are higher in the *fetal* compartment of male fetuses, there is no association between fetal sex and *maternal* serum concentrations of any androgen ([@DMU008C197]). The association between fetal sex and androgen levels, T or A4, in the fetal compartment, including serum and amniotic fluid, is consistent with androgen biosynthesis within Leydig cells of the fetal testis ([@DMU008C215]). Therefore, increased T and A4 levels in the amniotic fluid of male fetuses may reflect androgens excreted in fetal urine ([@DMU008C158]). The tissue origin and cause of the increase in androgens in maternal circulation during pregnancy remains uncertain but is likely to involve production from the ovary or placenta as discussed below.

### Tissue origin of androgen synthesis during pregnancy {#s3a5}

Within the ovary, androgens are synthesized in small luteal cells (SLC) of the corpus luteum (former theca cells of ovarian follicle) ([@DMU008C210]). Once pregnancy occurs, it is plausible that SLC stimulation by human chorionic gonadotrophin (hCG), which is elevated in first trimester, results in the reported increase in T levels at this time ([@DMU008C30]; [@DMU008C132]). However, hCG levels reach a peak at the end of first trimester and then decline, in contrast to T, which increases steadily, suggesting either an alternative regulation of androgen production by the corpus luteum or an alternative source of androgen increase following the end of the first trimester ([@DMU008C30]). Studies on women with premature ovarian failure (POF) who become pregnant following *in vitro* fertilization (IVF) with donor oocyte transfers suggest that the ovary is the major contributor to circulating concentrations of T and A4 during pregnancy ([@DMU008C39]). Such women were shown to have significantly lower levels of T and A4 when compared with pregnant women without POF. Perhaps not surprisingly, such studies are yet to be replicated by other research groups.

In addition to the maternal ovary, the maternal adrenal is an important source of androgen production throughout pregnancy. Indeed maternal and fetal virilization due to androgen excess have been reported in cases of adrenal adenomas ([@DMU008C82]). Studies in baboons showed that the maternal adrenal production of DHEA and DHEAS is suppressed during pregnancy by E2; this is in line with a reported decrease in DHEAS in maternal circulation throughout pregnancy ([@DMU008C7]; [@DMU008C254]; [@DMU008C243]). These studies demonstrated that removal of the fetus but not the placenta (fetectomy), in order to eliminate a fetal source of DHEA/DHEAS, induced a decline in E2 and an increase in DHEA/DHEAS levels in the maternal circulation ([@DMU008C5]; [@DMU008C7]). The decrease in E2 is probably due to withdrawal of fetal precursors for E2 formation. Interestingly, the authors showed that exogenous E2 could inhibit the fetectomy-induced increase in DHEA/DHEAS. The observation that metabolic clearance rate of DHEA/DHEAS remained unchanged before and after E2 administration, led authors to conclude that the estrogen-induced decline in maternal DHEA/DHEAS levels reflected a decrease in maternal adrenal production of these androgens.

Despite the prevailing belief from studies from 1960s that the placenta does not hold the metabolic capacity to synthesize androgens de novo, but relies solely on fetal androgens, a recent study has demonstrated that placental syncytiotrophoblast (but not cytotrophoblast) can synthesize androgens ([@DMU008C188]; [@DMU008C224]; [@DMU008C70]). Specifically, syncytiotrophoblast expresses both mRNA and protein of the metabolising enzyme CYP17, which converts C21 steroids (such as P4) to C19 steroids (such as T). The syncytiotrophoblast has been confirmed to have CYP17 activity *in vitro* ([@DMU008C70]).

The non-pregnant human myometrium has been shown to possess the metabolic capacity to convert A4 to T and DHT *in vitro*, but whether this system is functional in pregnancy is unknown ([@DMU008C110]). Consistent with this, a more recent study has reported that myometrium, derived from non-pregnant and early pregnant pig uteri, can synthesize A4 and T *in vitro* ([@DMU008C80]). Whether the cervix during pregnancy has the metabolic capacity to synthesize androgens is unknown.

Figure [3](#DMU008F3){ref-type="fig"} summarizes possible sites for androgen production in the materno-placental unit. Figure 3Maternal sites of androgen synthesis. The maternal adrenal gland secretes DHEA, DHEAS, A4 and T to the maternal circulation, from which androgens get distributed to peripheral tissues. Placenta is an additional site for *de novo* synthesis of A4 and T synthesis. Ovaries can also produce and secrete T, A4 and DHEA into maternal circulation. Myometrium can also synthesize A4, T and DHT. Finally, DHEA and T can be generated from precursors by androgen metabolizing enzymes. DHEA, dehydroepiandrosterone; T, testosterone; DHT, dihydrotestosterone; DHEAS, dehydroepiandrosterone sulphate; A4, androstenedione.

### Androgen clearance during pregnancy {#s3a6}

The concentrations of androgens measurable in blood (Pc) are also influenced by their metabolic clearance rate (MCR), the volume of blood cleared of a steroid per unit time ([@DMU008C16]). The blood production rate of an androgen (Pb) is the amount of androgen entering circulation from all possible sources (endocrine glands and periphery). This can be calculated according to the formula Pb = MCR x Pc and it represents an approximation of daily production rate of the steroid ([@DMU008C93]). The MCR of androgens, which represents the summation of individual organ clearance rates, is highly influenced by the amounts of circulating SHBG, which reduces the peripheral breakdown of androgens ([@DMU008C263]).

Soon after implantation, the production of maternal P4, E2 and androgens by the corpus luteum increases significantly ([@DMU008C66]; [@DMU008C241]; [@DMU008C196]; [@DMU008C126]; [@DMU008C266]; [@DMU008C76]; [@DMU008C29]; [@DMU008C240]). Corpus luteum-derived E2 stimulates liver SHBG synthesis leading to an increase in SHBG levels ([@DMU008C268]; [@DMU008C114]). The increase in SHBG should decrease the availability of fT and therefore lower the clearance of T and DHT. Indeed, it has been reported that the MCR of T and DHT is lower during the first three months of pregnancy compared with the non-pregnant state; however, DHT and T blood production rates are unchanged ([@DMU008C207]). These finding are in agreement with a study in guinea-pigs, where pregnancy induced a 2-fold decrease in MCR of T ([@DMU008C56]).

In contrast to T and DHT, the MCR of DHEA and DHEAS increases 2- and 5-fold, respectively, starting at mid-pregnancy ([@DMU008C84]; [@DMU008C19]; [@DMU008C21]). This phenomenon may reflect the metabolism of these steroids in the feto-placental unit, as both steroids are important as estrogen precursors ([@DMU008C90]; [@DMU008C136]). In addition to the increase in the MCR of DHEAS, its production rate by maternal adrenals increases in pregnancy ([@DMU008C156]). The net result is lower DHEAS levels in the maternal serum at the end of first trimester in comparison with the non-pregnant state ([@DMU008C243]). For A4, although pregnancy does not induce changes in the MCR, the production rate is increased 2-fold, explaining the observed increase in A4 in the blood ([@DMU008C20], [@DMU008C21]; [@DMU008C40]).

In conclusion from the above studies, it is understood that changes in the production of androgens (predominantly in the ovary and to a lesser extent in the adrenals and periphery) and the MCR occurring during pregnancy may all have an impact on androgen concentrations in the circulation. Of note, changes in concentrations of circulating androgens may not reflect the bioavailability of these steroids in target tissues and therefore their potential to play a role in the physiology of tissues such as the myometrium, cervix and placenta. The role of the increase in androgen levels during pregnancy has been understudied, although a number of adverse pregnancy outcomes have been correlated with impaired maternal androgen levels. These studies are discussed below.

Androgens and adverse pregnancy outcomes {#s3b}
----------------------------------------

Considering the adverse effects of increased circulating androgens in non-pregnant women, such as in PCOS, one would assume that the physiological pregnancy-induced increase in androgen levels could potentially have similar detrimental effects. However, it is generally accepted that pregnancy-specific mechanisms are activated to protect both the mother and fetus from pregnancy-induced androgen excess ([@DMU008C100]). In the absence of these 'protective' mechanisms, high levels of androgens would cause hirsutism and/or virilization of both mother and female fetus.

Maternal 'protective' mechanisms include (i) the physiological increase of maternal circulating SHBG, which binds and inactivates elevated androgens ([@DMU008C98]) (ii) the pregnancy-induced rapid elevation of P4, which competes for AR binding ([@DMU008C233]; [@DMU008C24]) and (iii) P4 having an affinity for 5α-reductase resulting in an inhibition of the conversion of T to the more potent DHT ([@DMU008C102]; [@DMU008C34]). Due to these mechanisms, pregnancy itself may reduce the clinical manifestation of pre-existing or pathological pregnancy-induced hyperandrogenic conditions ([@DMU008C186]; [@DMU008C50]). The most common hyperandrogenic conditions are known as 'non-tumour ovarian hyperandrogenism' and include PCOS, hyperreactio luteinalis (HL) and pregnancy luteoma ([@DMU008C116]). Numerous cases of HL, occurring predominantly during the second or third trimester and caused by high β-human chorionic gonadotrophin (β-hCG) levels, have been reported ([@DMU008C95]; [@DMU008C257]; [@DMU008C9]). These studies highlight that, in spite of the protective mechanisms, a small fraction of women with HL exhibit virilization and/or hirsutism, although their female fetuses are hardly ever virilized ([@DMU008C100]; [@DMU008C79]; [@DMU008C103]; [@DMU008C11]; [@DMU008C257]; [@DMU008C260]; [@DMU008C2]; [@DMU008C9]; [@DMU008C12]). Although most maternal hyperandrogenic symptoms of HL resolve post-partum, HL is highly associated with adverse pregnancy outcomes such as pre-eclampsia (PE) and PTB ([@DMU008C86]; [@DMU008C91]; [@DMU008C150]; [@DMU008C14]; [@DMU008C99]; [@DMU008C229]; [@DMU008C142]). Other hyperandrogenic disorders, which are generally very rare, include fetal-induced hyperandrogenism, due to fetal aromatase deficiency (FAD), iatrogenic hyperandrogenism, caused by exogenous androgen administration and adrenal tumour hyperandrogenism ([@DMU008C51]).

Fetal 'protective' mechanisms largely include the metabolism of androgens in the placenta ([@DMU008C224]; [@DMU008C228]). Specifically, the aromatase complex within the placenta plays a critical role in the protection of fetus from the mother\'s androgens as this enzyme rapidly converts T or A4 to E1 and E2, respectively ([@DMU008C63]; [@DMU008C18]; [@DMU008C96]; [@DMU008C178]; [@DMU008C228]). The efficacy of this placental barrier to androgens is evidenced by studies showing that women with hyperandrogenic disorders during pregnancy, such as PCOS, do not necessarily deliver virilized female fetuses ([@DMU008C230]; [@DMU008C71]). On the other hand, women with rare FAD can deliver virilized fetuses, again demonstrating the crucial importance of placental aromatase ([@DMU008C220]; [@DMU008C140]). Taken together, these studies show that pregnancy is associated with protective mechanisms, which ameliorate both maternal and fetal effects of the androgen increase associated with normal pregnancy physiology.

Besides the physiological androgen increase, numerous studies have explored the association of impaired androgen increases during pregnancy, and factors such as maternal age and sex of the baby, with pregnancy outcome. Women with PCOS, who have higher androgen levels than healthy pregnant women, are reported to have an ∼6% higher risk of delivering preterm than women without PCOS (Sir-Petermann et al., 2005; [@DMU008C275]). However, androgen excess might not be the only reason for early birth in these women, as PCOS is also associated with an increase in many inflammatory mediators, which may contribute to PTL ([@DMU008C58]). A study investigating the association of birth size of the offspring with maternal androgens has shown that elevated T is positively associated with *in utero* growth restriction ([@DMU008C37]). In addition, women pregnant with male fetuses are at greater risk of delivering preterm ([@DMU008C152]; [@DMU008C278]), a phenomenon sometimes attributed to the fact that pregnancies with male fetuses have higher levels of androgens in the fetal compartment compared with female fetuses. However, there is no evidence that the relationship between higher androgen levels in the fetal compartment and PTB is causal. In contrast to the positive association between androgen levels (at least in the fetal compartment) and the presence of a male fetus and PTB, increasing maternal age (which is negatively associated with maternal androgen levels in pregnancy) is known to be a risk factor for preterm deliveries ([@DMU008C13]; [@DMU008C36]). Recently, a specific change in the sequence of the fetal *AR* gene has been associated with predisposition to PTB ([@DMU008C117]). In particular, a linkage analysis study revealed that the exon-1 of *AR* of the offspring who was born preterm had more repetitions of a sequence encoding for a site in the domain involved in ligand activation ([@DMU008C117]). Abnormal increase in androgens during pregnancy has been additionally correlated with the development of gestational diabetes, which is further associated with PTB ([@DMU008C73]; [@DMU008C1]; [@DMU008C259]; [@DMU008C4]; [@DMU008C164]). This is probably due to the role of androgens in modulation of insulin secretion from the pancreas and inhibition of glucose uptake in fat and muscle cells ([@DMU008C45]; [@DMU008C193]). The mechanism linking the two hormonal axes is poorly understood and, interestingly, has not been considered or explored during pregnancy. Increased T levels in the maternal circulation at third trimester have been associated with the incidence of PE, suggesting T as a predictive marker ([@DMU008C88]; [@DMU008C137]; [@DMU008C217]; [@DMU008C229]). In this context, placentae from preeclamptic pregnancies have higher expression levels of AR in both male and female fetuses ([@DMU008C212]). Therefore, it is possible that AR signalling in the placenta contributes to the pathology of PE.

The association of androgen levels with preterm delivery has been studied in a few primate studies. For example, continuous administration of A4 to pregnant rhesus monkeys from early gestation or for a period of 48 h during third trimester resulted in preterm initiation of myometrial contractions and cervical dilatation leading to preterm delivery ([@DMU008C75]; [@DMU008C153]). In these studies, preterm delivery was associated with an increase in E2 in maternal circulation, suggesting conversion of A4 to E2 in the placenta. [@DMU008C167]) later supported that notion by showing that the preterm phenotype could be rescued by administration of an aromatase inhibitor. However, in other studies, direct administration of E2 or E1 to pregnant primates failed to induce preterm delivery ([@DMU008C173]; [@DMU008C6]). Therefore, it is likely that a physiological increase in androgen levels in maternal circulation from the start to end of pregnancy holds the key to term pregnancy. In support of this notion, abnormal changes in androgens levels at the start of pregnancy have been associated with spontaneous abortions or recurrent miscarriages. For example, spontaneous abortion was shown to occur in women whose androgen levels failed to increase at the beginning of pregnancy ([@DMU008C17]). On the other hand, women with recurrent miscarriages had significantly higher levels of T, A4 and T/SHBG ratio compared with women without recurrent miscarriages ([@DMU008C175]).

Although these studies emphasize how the normal increase in androgen levels might be pivotal for maintenance of pregnancy and development of the fetus, they fail to show a consistent relationship between either androgen excess or androgen deficiency and pregnancy problems. What is more, the mechanism by which androgens impact pregnancy outcomes has not been fully understood. Below we discuss the effect of androgens on cervical remodelling and myometrial function, the key processes in determining the timing of delivery. Particular focus is paid to myometrial smooth muscle cell (MSMC) physiology and the ability of androgens to interact with the contractile machinery of the cell.

The role of androgens in CR {#s3c}
---------------------------

### Structure of cervix during pregnancy {#s3c1}

The cervical stroma is composed of fibroblasts, smooth muscle cells (SMCs), epithelial cells and immune cells ([@DMU008C280]). These cells secrete an extracellular matrix (ECM), which consists primarily of collagen, glycosaminoglycans and proteoglycans. Hormones including progestogens and E2, relaxin and prostaglandin can alter ECM composition and affect the mechanical strength of the cervix ([@DMU008C65]; [@DMU008C226]; [@DMU008C113]; [@DMU008C89]). The consequence of this process is remodelling of the cervix, which can be divided into four stages: softening (first trimester), ripening (second trimester), dilatation (third trimester) and reconstitution of the non-pregnant cervix post-partum ([@DMU008C194]). Each stage has a characteristic collagen and proteoglycan composition as the tissue re-organizes and prepares for the next steps in the parturition process ([@DMU008C272]). CR is characterized by a 60% decrease in collagen and proteoglycan levels and occurs in parallel with an increase in collagenase activity, which itself is involved in collagen catabolism and disturbance of collagen bundles ([@DMU008C64]; [@DMU008C171]). However, collagen synthesis increases in the cervix at term due to collagen turnover being balanced between production and degradation ([@DMU008C64]). Structural abnormalities of the cervix have been associated with an increased risk of PTB, thus a better understanding of the physiology of cervical remodelling is crucial (reviewed by [@DMU008C170]).

### The role of androgens in CR {#s3c2}

Numerous human and animal studies have explored the role of androgens in the cervix, particularly during pregnancy ([@DMU008C161], [@DMU008C162]; [@DMU008C211]; [@DMU008C160]; [@DMU008C244]; [@DMU008C208], [@DMU008C209]; [@DMU008C276]; [@DMU008C67]; [@DMU008C115]; [@DMU008C112]). These studies formed the basis of a hypothesis, whereby androgens regulate cervical remodelling, particularly CR at term. Table [II](#DMU008TB2){ref-type="table"} summarizes key findings from these studies. Collectively, these reports provide enough evidence that the fetal androgen, DHEAS, promotes CR by enhancing collagenase activity and thus decreasing fibril collagen organization. Table IIStudies on the effect of androgen administration on CR.AndrogenDoseSpecies/tissueKey findingsReferenceDHEAS0.01 mg/ml\
0.1 mg/mlHuman\
*In vitro*: HCF derived from term pregnancy↑ IL-8 in conditioned medium\
↑ IL receptor in HCF[@DMU008C115]DHEAS200 mgHuman\
*In vivo*: term pregnant women (\>38 weeks)↑ Bishop score\
↑ Collagenase activity[@DMU008C161], [@DMU008C162]DHEAS200 mgHuman\
*In vivo*: term pregnant women (38--42 weeks)↑ Bishop score\
↑ Collagenase activity\
↑ E2 in maternal serum[@DMU008C160]DHEAS50--100 mgHuman\
*In vivo*: term pregnant women (38--42 weeks)↑ Bishop score\
↓ Time to delivery\
No side effects[@DMU008C161], [@DMU008C162]DHEAS100 mgHuman\
*In vivo*: term pregnant multiparous and nulliparous women (\>38 weeks)↑ Bishop score\
↓ Duration of labour in nulliparous women\
↓ Time to delivery in nulliparous\
No side effects[@DMU008C211]DHEAS50--200 mgHuman\
*In vivo*: term pregnant singleton and twin pregnancies (\>39 weeks)↑ Bishop score\
(higher correlation of Bishop score with twin pregnancies)\
↑ E2 levels in maternal serum\
(higher correlation of E2 levels with twin pregnancies)\
No change in E1, E3 levels in maternal serum.[@DMU008C244]DHEAS1 μMRabbit\
*In vitro*: CCs derived from term pregnancy↑ Collagenase levels\
No effect of E2 or DHEA treatment[@DMU008C208]DHEAS1 μMRabbit\
*In vitro*: CCs derived from term pregnancy↑ Collagenase levels\
No effect on collagen levels[@DMU008C209]DHEAS10 mgRabbit\
*In vivo*: term pregnancy↑ Collagenase activity\
↓ Collagen content\
Combined DHEAS + IL-8 (100 ng) treatment-induced neutrophil infiltration\
Combined treatment produced maximal decrease in collagen content[@DMU008C67]DHEAS100 mgRat\
*In vivo*: term pregnancy (day 16)↓ Collagen content\
↑ Collagenase activity[@DMU008C276]DHEA0.01 mg/ml\
0.1 mg/mlHuman\
*In vitro*: HCF derived from term pregnancyIncrease of IL-8 in conditioned medium\
Increase of IL receptor in HCF[@DMU008C115]DHT2 mgRat\
*In vivo*: term pregnancy (15 day)↓ Cervical resistance\
↓ Proteoglycan\
mRNA\
Flutamide treatment (10 mg)\
↑ Cervical resistance\
↑ Proteoglycan mRNA[@DMU008C112][^2]

### Mechanism of androgen effect on CR {#s3c3}

The physiology or pharmacology of androgen effects on CR is not fully understood. In support of a physiological effect of DHEAS on CR, one study has reported that DHEAS levels are significantly correlated with favourable outcome according to the Bishop score, i.e. higher levels of DHEAS in women with successful (spontaneous) CR compared with women in need of induction of labour ([@DMU008C121]). DHEAS administration has been additionally positively correlated with increases in E2 levels in maternal serum ([@DMU008C244]). Therefore, it has been argued that DHEAS is metabolized to estrogens in term cervix, which in turn initiates CR. However, studies examining such effects showed that administration of estrogens alone fails to ripen the cervix ([@DMU008C247]; [@DMU008C129]; [@DMU008C52]). Notably DHT, which cannot be metabolized to estrogens, also promotes CR, implying an androgen-specific effect ([@DMU008C112]). Interestingly, mice with knockout (KO) of 5α-reductase type 1 develop an abnormal cervix that fails to ripen at labour ([@DMU008C146]). 5α-reductase type 1 converts T to DHT and is the predominant enzyme expressed in cervix at term ([@DMU008C144]). Administration of a 5α-reduced androgen, a metabolite of DHT, 5alpha-androstane-3alpha, 17β-diol, rescues the impaired phenotype of 5α-reductase type 1 KO animals, allowing normal CR ([@DMU008C145]). The latter finding suggests local conversion of androgens to other (more potent) androgen metabolites as the underlying mechanism in the initiation of CR.

Although poorly explored, there is some evidence to suggest that the mechanism of DHEAS action on the collagenase increase is indirect and is mediated via DHEAS-stimulated neutrophil secretion of the proteolytic enzyme ([@DMU008C67]; [@DMU008C151]). Indeed, DHEAS action on CR has been correlated with increased levels of IL-8 cytokine involved in chemotaxis of neutrophils recruited in cervix towards term ([@DMU008C115]; [@DMU008C151]).

The involvement of AR in mediation of CR by androgens has been recently examined ([@DMU008C112]). In that study, antagonism of AR by flutamide inhibited events associated with CR, such as a decrease in collagen fibril organization, a decrease in cervical resistance and a decrease in proteoglycan synthesis in pregnant rats pre-treated with DHT on Day 16, suggesting genomic signalling ([@DMU008C112]). Although this study did not examine AR expression in the cervix, other immunohistochemical studies in non-pregnant and pregnant humans and canine cervix have demonstrated cervical expression of AR ([@DMU008C270]; [@DMU008C262]; [@DMU008C112]; [@DMU008C264]). In addition, it has been reported that androgens up-regulate AR expression in the human cervix ([@DMU008C256]).

All the above reports suggest that DHEA and DHT might promote CR via a pathway impacting collagenase synthesis and/or activity. Although the mechanism of this action is not well established, there is some evidence that it is possibly mediated via metabolism of androgens to reduced androgens and/or genomic signalling through AR. This notion needs more investigation. In addition, the role of androgens and androgen signalling in the cervical endothelial/epithelial cells and cervical SMCs in terms of cervical remodelling throughout pregnancy is surprisingly unexplored.

The role of androgens in myometrial function {#s3d}
--------------------------------------------

### MSMCs changes during pregnancy {#s3d1}

MSMCs are specialized contractile cells that, in contrast to skeletal and SMCs, exhibit cellular plasticity, which enables reversible differentiation into different phenotypes ([@DMU008C83]; [@DMU008C251]). Studies of myometrium during rat pregnancy have demonstrated that MSMCs undergo four phenotypic changes throughout gestation ([@DMU008C223]). Briefly, these are a proliferative stage, a synthetic stage, a contractile stage and, finally, a labour stage. In early pregnancy, following implantation of the conceptus, MSMCs proliferate rapidly and become hyperplastic. Hyperplasia is believed to be mediated by hormone signalling and growth factors, such as IGF-1 and EGF, have been shown to be involved in induction of the so-called proliferative phenotype ([@DMU008C222]). Following the proliferative phase, MSMCs undergo an intermediate synthetic phase starting on Day 14 of rodent pregnancy ([@DMU008C141]). The synthetic phenotype is characterized by increased synthesis of ECM and cellular hypertrophy of MSMCs ([@DMU008C223]). On Day 21 of rodent gestation, uterine myocytes switch to a contractile phenotype ([@DMU008C168]; [@DMU008C74]; [@DMU008C221]). Differentiation into a contractile phenotype is largely attributed to mechanical stretch ([@DMU008C147]; [@DMU008C138]; [@DMU008C238]; [@DMU008C246]). MSMCs undergo a final phase of differentiation following initiation of labour, the so-called labour phenotype ([@DMU008C223]). At this point, the myometrium develops synchronous contractions and expresses a number of contraction-associated proteins (CAPs), such as connexin 43 (Con43), oxytocin receptor (OXTR) and prostaglandin F receptor ([@DMU008C81]; [@DMU008C232]; [@DMU008C239]; [@DMU008C69]; [@DMU008C195]). Returning MSMCs to a non-pregnant state involves rapid apoptosis ([@DMU008C202]; [@DMU008C174]; [@DMU008C223]).

A recent study, conducted in rats, reported that AR is highly expressed in MSCMs during the proliferative stage and progressively declines towards the end of pregnancy, suggesting a role (at least in this species) in establishment of myometrial growth at early stages of pregnancy ([@DMU008C133]). Liu *et al*. additionally showed that the AR decrease itself affects IGF-1 receptor (IGF-1R) stability and thus down-regulates downstream cascades that IGF-1 is involved in (including P13K/Akt, which is highly important in proliferative pathways) ([@DMU008C133]). Besides rats, a significant decrease in AR expression occurs in porcine myometrium 3 weeks prior to labour ([@DMU008C234]). A human microarray study also showed AR gene down-regulation in the myometrium during preterm (0.4-fold) and term labour (0.3-fold) compared with non-labouring myometrium, but the protein expression was not determined ([@DMU008C23]). Thus, androgen signalling in MSMCs is likely to be involved in proliferative pathways pivotal for 'building' of the myometrium in the early stages of pregnancy.

### The role of androgens in myometrial contractility {#s3d2}

Androgens have been demonstrated to relax SMCs, such as rabbit and pig trachea, rat mesenteric arterial bed, rat thoracic aorta and human coronary artery ([@DMU008C183], [@DMU008C184]; [@DMU008C43]; [@DMU008C46]; [@DMU008C204]; [@DMU008C245]; [@DMU008C185]; [@DMU008C120]; [@DMU008C27]; [@DMU008C163]; [@DMU008C42]). [@DMU008C200]) was the first to suggest that androgens may have an inhibitory action on uterine muscle contraction. Following a 4-day administration of 12 mg of testosterone propionate (a small fast-acting ester of testosterone) to ovariectomized non-pregnant rabbits, he examined the contractile response of their uterus to 1 unit of injected oxytocin both *in vivo* and *in vitro*. The uterus of T-treated rabbits did not respond to oxytocin administration in contrast to the uterus of control rabbits. However, the spontaneous contractile activity of the uterus was only slightly affected ([@DMU008C200]). Following Robson, some other studies have demonstrated similar relaxing effects of various androgens including T, DHT, A4 and DHEAS on the myometrium of non-pregnant rats and non-pregnant and pregnant humans ([@DMU008C122]; [@DMU008C183], [@DMU008C184]; [@DMU008C185]). The findings from these studies are summarized in Table [III](#DMU008TB3){ref-type="table"}. The relaxing effect occurs only in pharmacological concentrations (micromolar) and is rapid, suggesting non-genomic mechanism of action ([@DMU008C182]; [@DMU008C10]; [@DMU008C250]). A logical assumption would be that the observed effect of androgens might not occur physiologically because physiological androgen concentrations are in a nanomolar range. However, understanding the molecular pathways employed by androgens in modulation of myometrial relaxation could help in the development of new tocolytic agents to manage preterm spontaneous contractions. We discuss below the current evidence for possible molecular mechanisms by which androgens might elicit relaxing effects in myometrium. Table IIIStudies on the effect of androgen on myometrial contractions.AndrogenDoseSpecies/tissueKey findingsReferencesT, DHEA, androstanediol, androsterone, A4, 5α-DHT, 5β-DHT10--100 μMRat (non-pregnant)\
*Ex vivo*: myometrial stripsSpontaneous contractions inhibited rapidly (\<30 min) by all androgens\
Potency:\
androstanediol, androsterone \>5β-DHT \> T = A4 = DHEA = 5α-DHT[@DMU008C122]T, DHEA, androstanediol, androsterone, 5β-DHT3--100 μMRat (non-pregnant)\
*Ex vivo*: myometrial stripsTonic contractions (KCl induced) inhibited rapidly (\<30 min) by all androgens\
Potency:\
androsterone = androstanediol \>5β-DHT \> T[@DMU008C182]androstanediol, androsterone, 5α-DHT, 5β-DHT3--100 μMRat (non-pregnant)\
*Ex vivo*: myometrial stripsSerotonin-induced contractions inhibited rapidly (\<30 min) by all androgens[@DMU008C183], [@DMU008C184])androstanediol, androsterone, 5α-DHT, 5β-DHT3--100 μMRat (non-pregnant)\
*Ex vivo*: myometrial StripsAcetylcholine-induced contractions inhibited rapidly (\<30 min) by all androgens[@DMU008C183], [@DMU008C184])androstanediol, androsterone, 5α-DHT, 5β-DHT3--100 μMRat (non-pregnant)\
*Ex vivo*: myometrial stripsOxytocin-induced contractions inhibited rapidly (\<30 min) by all androgens[@DMU008C181]T, DHEA, DHT, 5α-DHT, 5β-DHT, androstanediol, androsterone3--100 μMHuman (term pregnant, non-pregnant)\
*Ex vivo*: myometrial stripsSpontaneous contractions and tonic contractions (KCl induced)\
inhibited rapidly (\<30 min) by all androgens\
Potency:\
5β-DHT \> androsterone = DHEA = T \> 5α-DHT = androstanediol[@DMU008C185][^3]

### Mechanism of MSMC contraction {#s3d3}

MSMCs are myogenic, which means that they can contract spontaneously ([@DMU008C251]). The membrane potential in MSMCs is not stable. Spontaneous depolarization of membrane potential, fired by alterations in membrane currents and ion channels, occurs during pregnancy. A decrease in membrane potential triggers myocyte contractile activity and leads to spontaneous contractions; conversely, amplification of membrane potential to a resting −50 mV maintains the uterus in a quiescent state ([@DMU008C166]; [@DMU008C190]). The upstroke of MSMCs membrane action potential (i.e. the initial decrease in membrane potential) is predominantly due to calcium (Ca^2+^) entry, whereas repolarization occurs as a result of blockage of Ca^2+^ channels ([@DMU008C166]). The key biochemical event in spontaneous MSMC contraction is an increase in intracellular Ca^2+^ (\[Ca^2+^\]) from 10^−7^ to 10^−6^ M ([@DMU008C104]). This increase is the outcome of extracellular influx of Ca^2+^ and/or release of Ca^2+^ from the sarcoplasmic reticulum (SR). The entry of Ca^2+^ is mediated via a variety of Ca^2+^ channels classified into voltage-operated Ca^2+^ channels (VOCCs) and voltage-independent Ca^2+^ channels (including receptor-operated Ca^2+^ channels, ROCCs) ([@DMU008C273], [@DMU008C274]; [@DMU008C77]; [@DMU008C169]). ROCCs are regulated by an agonist-receptor interaction ([@DMU008C92]). Receptors that interact with ROCCs upon ligand binding are G protein coupled receptors (GPCRs), such as the OXTR. GPCRs can activate the inositol triphosphate (IP3) pathway leading to release of Ca^2+^ from SR via activation of phosphoinositide phospholipase C and hydrolysis of PIP2 ([@DMU008C154]). The resulting increase in \[Ca^2+^\] leads to formation of a complex between calmodulin and myosin light chain kinase, which then phosphorylates light chains on myocin (MLC) ([@DMU008C108]). The latter event allows binding of actin to myocin leading to cross-bridge cycling, which then causes contraction ([@DMU008C61]). Extrusion of \[Ca^2+^\] in MSMCs can occur by reverse processes and is mediated by two major transporters: plasma membrane Ca^2+^ ATPase (PMCA) and the Na^+^/Ca^2+^ exchange pump (NCX) ([@DMU008C218]). Studies examining mechanisms by which Ca^2+^ ions are removed from the cytoplasm in isolated rat MSMCs show that PMCA accounts for 85% of the Ca^2+^ efflux ([@DMU008C218]).

Besides VOCCs, ROCCs, PMCA and NCX, Ca^2+^ flux is highly influenced by MSMC membrane fluidity. A proton nuclear magnetic resonance (NMR) spectroscopy study investigating various parameters of myometrial membrane fluidity at pregnancy, including phospholipid double bonds, fatty acid chain length and the Ch/phospholipid ratio, reported that MSMC membrane fluidity is increased with labour ([@DMU008C191]). Cell membrane fluidity is modulated by changes in the concentration of membrane Ch ([@DMU008C219]). Ch is a component of the lipid bilayer, which integrates into the membrane by placing its steroid ring next to the hydrocarbon chains and locating its hydroxyl group close to the head of phospholipid ([@DMU008C258]; [@DMU008C227]; [@DMU008C107]). High Ch results in a stiff membrane and thus reduces membrane fluidity, whereas low Ch promotes membrane fluidity. Decreased membrane fluidity is characterized by inhibition of Ca^2+^ channels such as VOCCs and ROCCs ([@DMU008C111]; [@DMU008C219]). Administration of Ch *in vitro* decreases \[Ca^2+^\] and inhibits the phasic contractions in MSMCs of rats and humans ([@DMU008C236]; [@DMU008C279]). On the other hand, depletion of Ch from the rat MSMC membrane with methyl-beta-cyclodextrin treatment causes an increase in cell excitability and contraction ([@DMU008C111]; [@DMU008C219]). High Ch has been correlated with increased activities of NCX and PMCA, which is consistent with their roles in promoting Ca^2+^ efflux ([@DMU008C177]; [@DMU008C124]; [@DMU008C261]).

### Non-genomic interactions of androgens with the contractile machinery {#s3d4}

Possible interactions of androgens with the MSMC contractile machinery, including interactions with VOCCs, ROCCs, the lipid bilayer, gap junctions and membrane receptors, which may result in the inhibition of contraction, are discussed below.

#### Androgens and VOCCs {#s3d4a}

High K^+^ in the extracellular space induces cell membrane depolarization, which in turn results in opening of Ca^2+^ channels (VOCCs) and an increase in \[Ca^2+^\]. In addition to the relaxing effect of androgens on spontaneous myometrial contractions, 5β-DHT rapidly relaxes tonic contractions (induced by high K^+^) and decreases single MSMC \[Ca^2+^\], while removal of the androgen reverses the effect ([@DMU008C185]). A logical explanation of the mechanism of the relaxing effect of the androgen in that case would be via inhibition of VOCCs. However, it is not clear whether the effect of androgens involves a physical interaction with VOCCs or is indirect.

#### Androgens and ROCCs {#s3d4b}

Besides VOCCs, there is some evidence that androgens may be able to block ROCCs. For example, androgens can relax rat uterine contractions induced by serotonin, oxytocin and acetylcholine *in vitro* ([@DMU008C181]; [@DMU008C183], [@DMU008C184]). Oxytocin, acetylcholine and serotonin receptors are GPCRs. Their activation leads to subsequent activation of extracellular Ca^2+^ influx via ROCCs and/or Ca^2+^ influx from SR via the IP3 pathway ([@DMU008C128]; [@DMU008C249]). It is possible that androgens exert their effects on oxytocin-induced contraction via blockage of IP3 pathway and release of SR Ca^2+^. However, inhibition of the SR Ca^2+^ release is not sufficient for complete blockage of the overall Ca^2+^ influx ([@DMU008C123]). Therefore, a logical assumption would be that androgens block the ROCC-associated Ca^2+^ influx rather than components of IP3 pathway. This notion is supported by the inability of T in another study to inhibit both caffeine- and carbachol- induced Ca^2+^ release (activators of IP3-pathway) in coronary SMC ([@DMU008C165]). Identical findings were reported in isolated rat thoracic aortic strips and porcine coronary arteries, where T could inhibit K^+^-induced but not caffeine-induced contractions ([@DMU008C48], [@DMU008C49]). There are no data on relaxing effect of androgens on a GPCR agonist-stimulated contractions (such as oxytocin and prostaglandin FP) induced contraction in human myometrium.

#### Androgens and the lipid bilayer {#s3d4c}

In a similar manner to Ch, it is plausible that Ch metabolites (including androgens) mediate non-genomic responses via direct penetration into the cell membrane and reduction in MSMC membrane fluidity. For example, hydrophobic androgens, such as DHT and T, have been shown to interact with the phospholipid bilayer of the negatively charged membrane ([@DMU008C62]; [@DMU008C255]). Such interactions may impair Ca^2+^ homeostasis due to an increase in the activity of PMCA. Regulation of PMCA by androgens is documented in different tissues. For example, in synaptosomal plasma membranes, PMCA activity increases 95% following 10 μM of T treatment ([@DMU008C54]). In addition, PMCA activity in kidney is increased following administration of 10 μM of T*,* as measured by *in vitro* assays where the ATP-dependent Ca^2+^ flux was determined by comparison of Ca^2+^ transport (implying PMCA activity) with and without exogenous addition of ATP ([@DMU008C59]). In line with the latter study, androgen deprivation induced by castration alters the immunochistochemical localization of PMCA in prostate epithelial cells with no changes in mRNA or protein levels ([@DMU008C47]). Additionally, the regulation of Ca^2+^-ATPase in SR activity by T has been explored in ventricular muscle of orchidectomized (ORX) rats ([@DMU008C271]). In that study, T treatment managed to prevent an ORX-induced decrease in Ca^2+^-ATPase activity. Collectively, an alternative mechanism for the non-genomic action of androgens in MSMC relaxation is proposed, whereby androgens penetrate the lipid bilayer and decrease membrane fluidity, resulting in an increase in PMCA activity and Ca^2+^ efflux. However, the effect of androgens on PMCA activity in the myometrium has not yet been explored and, thus, this hypothesis remains to be confirmed in this tissue.

#### Androgens and gap junctions {#s3d4d}

Increases in single SMC \[Ca^2+^\] initiates a synchronized increase in \[Ca^2+^\] in adjacent cells, a process mediated by gap junctions ([@DMU008C134]; [@DMU008C28]; [@DMU008C26]). Gap junction proteins increase the ability of MSMCs to generate synchronous contractions and mount a synchronous response to hormones or agents in the microenvironment of uterus at labour ([@DMU008C85]; [@DMU008C106]). Connexins are gap junction trans-membrane proteins that assemble to form a gap junction; Con43 is the predominant connexin involved in the initiation of MSMC contractions at term ([@DMU008C44]). A study in pregnant rats on a high Ch diet showed that high Ch is associated with a decrease in Con43 protein in the myometrium, suggesting possible implications for uterine contractility ([@DMU008C68]). A study in isolated rat cardiac myocytes demonstrated that gap junctional intracellular communication (GJIC) disturbance, by either silencing the gene for Con43 or by addition of specific drugs, such as heptanol, induced a significant reduction in Ca^2+^ transients, suggesting that Con43 may be involved in the regulation of basal Ca^2+^ signalling in these cells ([@DMU008C130]). Interestingly, an estrogenic compound 4-OH-TCB has been shown to act in a similar manner to heptanol and significantly block GJIC in rat myometrium ([@DMU008C253]). What is more, the same study showed that 4-OH-TCB could reduce contractions of rat myometrial strips, suggesting that the relaxing effect of 4-OH-TCB is mediated through blockage of GJIC. There is evidence that androgens can influence GJIC in isolated rat cardiac myocytes and Sertoli cells ([@DMU008C189]). One study demonstrated a dose-dependent (1--25 μM) inhibitory effect of T propionate on GJIC, which was reversed by T withdrawal and was unaffected by pre-incubation with AR antagonist, again implying a non-genomic effect of T ([@DMU008C189]). Based on these studies, it is tempting to hypothesize that androgens may induce relaxation of myometrium via direct interaction with the membrane proteolipidic structure, which might alter directly or indirectly the function of gap junction channels; however, more evidence in needed.

#### Androgens and ARs {#s3d4e}

A role for ARs in inhibition of myometrial contraction has been investigated ([@DMU008C185]). Flutamide-induced AR antagonism failed to inhibit the relaxing effect of 5β-DHT ([@DMU008C185]). Notably, in that study, flutamide was administered at a significantly lower concentration (10 μM) than the concentration of 5β-DHT (100 μM), thus it is not clear whether nuclear AR is involved in the relaxing effect. However, the rapid action of androgens on myometrial relaxation makes a genomic mechanism unlikely. On the other hand, a few reports have now demonstrated that AR can be recruited in non-genomic actions of androgens (reviewed in [@DMU008C97]). This mechanism involves the largely unexplored membrane AR (mAR). The mAR is hypothesized to be either a GPCR or a classic AR lacking a DNA-binding site; the latter is thought to have greater affinity for androgens compared with nAR ([@DMU008C119]; [@DMU008C78]; [@DMU008C277]). A study on airway SMCs showed that in addition to T, treatments with membrane impermable T conjugated to BSA (TBSA) could inhibit contraction, suggesting that T exerts its effects on the outer aspect of the membrane rather than in the cytoplasm ([@DMU008C120]). However, the downstream mechanism of mAR activation in that study was unclear. The structure of mAR is yet to be characterized in mammals and it is unknown whether it is utilized by androgens to inhibit MSMC contraction ([@DMU008C248]).

Collectively, the above studies allow us to hypothesize that androgen-induced MSMC relaxation is mediated via penetration of the androgen into the lipid bilayer where it affects molecules critical for generation of Ca^2+^ transients, including VOCCs, ROCCs, gap junctions and PMCA (Fig. [4](#DMU008F4){ref-type="fig"}). Figure 4Hypothetical targets of androgens in modulation of MSMC relaxation. Androgens are hypothesized to interact with contractile machinery of MSMCs via penetration into the lipid bilayer. This might promote PMCA to induce rapid Ca^2+^ efflux, block VOCCs and ROCCs and impair IGJC via effects on the gap junctions. PMCA, Ca^2+^ ATPase; VOCC, voltage-operated Ca^2+^ channels; ROCC, receptor-operated Ca^2+^ channels; IGJC, intercellular gap junctional communication.

Conclusions {#s4}
===========

There is growing evidence that androgens, which increase throughout gestation, might play a functional role in the physiology of pregnancy in parallel with the well-established roles of progestins and estrogens. Herein we reviewed what is currently known about roles played by androgens in two critical systems in biology of pregnancy and parturition, cervical remodelling and myometrial function.

There is evidence from *in vivo* and *in vitro* studies that androgens promote CR and, thus, assist initiation of labour. On the other hand, androgens appear to be effective in *in vitro* tocolysis of myometrial contractions. Although the action of androgens on cervical remodelling is possibly mediated via classical activation of genomic signalling via AR, it is unlikely that the same mechanism mediates androgen effects in myometrial contractility. In contrast, there is more evidence that AR acting within the nucleus is involved in the proliferation of MSMCs and, thus, may be important for the growth of myometrium at the beginning of pregnancy. Further investigations are required to fully understand the molecular events regulated by androgens in cervix and myometrium and their interplay with other signalling pathways. These investigations should potentially utilize animal models of adverse pregnancy outcomes, where targeted administration of androgens to either cervix or myometrium could be highly informative. In conclusion, research into the roles of androgens in cervical and myometrial function during pregnancy and parturition has the potential to inform new therapeutic strategies for management of pregnancy complications, such as PTL and PTB.
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[^1]: The table shows the mean concentrations of androgens as given in references quoted. tT, total testosterone; fT, free testosterone; SHBG, sex hormone binding globulin; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate; A4, androstenedione; DHT, dihydrotestosterone.

[^2]: DHEAS, dehydroepiandrosterone sulphate; DHT, dihydrotestosterone; HCF, human cervical fibroblast; CCs, cervical cells.

[^3]: DHEA, dehydroepiandrosterone; T, testosterone; DHT, dihydrotestosterone; DHEAS, dehydroepiandrosterone sulphate; A4, androstenedione.
